Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Asthma/obstructive pulmonary disease overlap: update on definition, biomarkers, and therapeutics

Asthma/obstructive pulmonary disease overlap: update on definition, biomarkers, and therapeutics Downloaded from http://journals.lww.com/co-allergy by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/04/2020 REVIEW URRENT Asthma/obstructive pulmonary disease overlap: PINION update on definition, biomarkers, and therapeutics August Generoso and John Oppenheimer Purpose of review Asthma/chronic obstructive pulmonary disease overlap (ACO) continues to be a poorly understood condition. This review discusses newly proposed criteria and potential biomarkers in ACO, to aid in diagnosis and research studies, and prudent therapeutic approaches. Recent findings A global expert panel proposed an operational definition consisting of major and minor criteria as a step toward defining ACO. Serum periostin and YKL-40 may serve as biomarkers for ACO. Clinically, a reasonable therapeutic approach to ACO is the early addition of a long-acting b-agonist (LABA) and/or a long-acting muscarinic antagonist (LAMA) to an inhaled corticosteroid (ICS). Summary Both the proposed criteria and the described biomarkers for ACO can help guide clinicians in identifying this condition as well as aid researchers in designing much needed future studies. In the meantime, clinicians can treat potential ACO patients using the above approach, until therapeutic studies in clearly defined ACO patients are performed. Keywords asthma/chronic obstructive pulmonary disease overlap, asthma/chronic obstructive pulmonary disease overlap syndrome, asthma, chronic obstructive pulmonary disease INTRODUCTION ACO does affect treatment choices, as http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in Allergy & Clinical Immunology Wolters Kluwer Health

Asthma/obstructive pulmonary disease overlap: update on definition, biomarkers, and therapeutics

Loading next page...
 
/lp/wolters-kluwer-health/asthma-obstructive-pulmonary-disease-overlap-update-on-definition-fnSaJKsksd

References (36)

Publisher
Wolters Kluwer Health
ISSN
1528-4050
eISSN
1473-6322
DOI
10.1097/ACI.0000000000000596
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/co-allergy by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/04/2020 REVIEW URRENT Asthma/obstructive pulmonary disease overlap: PINION update on definition, biomarkers, and therapeutics August Generoso and John Oppenheimer Purpose of review Asthma/chronic obstructive pulmonary disease overlap (ACO) continues to be a poorly understood condition. This review discusses newly proposed criteria and potential biomarkers in ACO, to aid in diagnosis and research studies, and prudent therapeutic approaches. Recent findings A global expert panel proposed an operational definition consisting of major and minor criteria as a step toward defining ACO. Serum periostin and YKL-40 may serve as biomarkers for ACO. Clinically, a reasonable therapeutic approach to ACO is the early addition of a long-acting b-agonist (LABA) and/or a long-acting muscarinic antagonist (LAMA) to an inhaled corticosteroid (ICS). Summary Both the proposed criteria and the described biomarkers for ACO can help guide clinicians in identifying this condition as well as aid researchers in designing much needed future studies. In the meantime, clinicians can treat potential ACO patients using the above approach, until therapeutic studies in clearly defined ACO patients are performed. Keywords asthma/chronic obstructive pulmonary disease overlap, asthma/chronic obstructive pulmonary disease overlap syndrome, asthma, chronic obstructive pulmonary disease INTRODUCTION ACO does affect treatment choices, as

Journal

Current Opinion in Allergy & Clinical ImmunologyWolters Kluwer Health

Published: Feb 1, 2020

There are no references for this article.